Latest News

STAT Plus: Some insurers are pushing back on the high price for a Novartis gene therapy

Barely a month after Novartis (NVS) won U.S. regulatory approval for its gene therapy — the most expensive in the world — nearly a dozen insurers are taking steps to restrict coverage, a trend that is concerning for gene therapies more broadly, according to a Wall Street analyst.

At issue is Zolgensma, a gene therapy product for infants with spinal muscular atrophy, or SMA, an inherited disease that causes progressive loss of muscle function. The most severe form of SMA causes infants to die or need permanent breathing support by the age of 2. The  “one-and-done” treatment is considered a miracle cure by some, but the $2.125 million price tag is controversial.

Continue to STAT Plus to read the full story…

Source link

Related posts

Nanobots Eat Up Nerve Agents and Release Life Saving Antidote


Alarmingly low rates of HIV testing among at-risk teenage boys


Medical News Today: Ocular migraine: Everything you need to know


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World